INTRODUCTION {#s1}
============

Angiogenesis is critical for the local invasion and progression of tumor cells \[[@R1]\]. The aberrant formation and proliferation of blood vessels is due to an imbalance in pro- and anti-angiogenic factors, with the first weighing more \[[@R2]\]. Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) are several positive regulators of angiogenesis \[[@R3]\]. Over the last decade, multi-targeted tyrosine kinase inhibitors (TKIs) have been developed and approved in clinical oncology practice \[[@R4]\].

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor of VEGFR, FGFR, PDGFR and RET \[[@R5], [@R6]\]. With its anti-angiogenic activity, and a direct effect on tumor cells by preventing relevant signaling pathways \[[@R6]--[@R8]\], lenvatinib has been observed to have promising effects in clinical trials for thyroid cancer \[[@R9], [@R10]\]. In February 2015, US FDA has approved lenvatinib for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) \[[@R9]\].

Lenvatinib has brought clinical benefits for patients, but adverse events (AEs) are inevitable such as hypertension, fatigue, proteinuria, nausea, decreased weight and abdominal pain, which may decrease the quality of life of patients and influence their acceptance of treatment \[[@R11], [@R12]\]. Therefore, we conducted a meta-analysis to estimate various AEs and clinical benefits of lenvatinib.

RESULTS {#s2}
=======

Literature search results {#s2_1}
-------------------------

We ran an initial broad search that yielded 422 unique articles after deletion of duplicates. After title and abstract screening, 344 were excluded since they were narrative review articles or interviews, or completely not associated with clinical assessment of lenvatinib. Forty were further excluded for they were conference abstracts based on published clinical trials, leaving 38 potentially relevant studies for full review. After estimating the full texts of these articles, 24 articles were ruled out for insufficient information. Ultimately, 14 eligible studies \[[@R13]--[@R26]\] involving a total of 978 patients met our meta-analysis criteria. Two articles \[[@R22], [@R26]\] with the same first author which had different study designs were both included in our study, one was a phase II trial, and the other was a phase III, randomized multicenter study. No additional unpublished trials were added to the literature search results. A flow diagram of the trial selection process is provided in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of the literature search and selection process](oncotarget-07-44545-g001){#F1}

Study characteristics {#s2_2}
---------------------

Of the studies that were included in the final analysis, 3 studies were based on thyroid cancer patients, 5 evaluated advanced solid tumors, 1 evaluated non-small-cell lung cancer, 1 was based on melanoma, 2 were performed on metastatic renal cell carcinoma, 1 was on advanced hepatocellular carcinoma and 1 on healthy adults. Schlumberger M \[[@R22]\] compared lenvatinib with placebo in radioiodine-refractory thyroid cancer patients, and Motzer RJ \[[@R19]\] used lenvatinib---either in combination with everolimus or as a single agent in patients with metastatic renal cell carcinoma. The characteristics of each trial are summarized in Table [1](#T1){ref-type="table"}.

###### Basic characteristics of the included articles

  First author        Year   Phase   Sample size                                                                 Gender    Age       Region                                      Histology                                                             Treatment arm                       Treatment regimen            
  ------------------- ------ ------- --------------------------------------------------------------------------- --------- --------- ------------------------------------------- --------------------------------------------------------------------- ----------------------------------- ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Schlumberger M^1^   2015   II      59                                                                          37        22        Mean 52                                     United States, United Kingdom, Australia, France, Italy, and Poland   MTC or DTC                          Lenvatinib                   Lenvatinib 24 mg Qd, 28-day cycles
  Hong DS^1^          2015   I       77                                                                          40        37        Median(range) 61.0(28--85)                  USA                                                                   Advanced solid tumor; Melanoma      Lenvatinib                   Lenvatinib 0.1--3.2 mg Bid (n=18); 3.2--12 mg Bid (n=33); 10 mg Bid (n=26)
  Cabanillas ME       2015   II      58                                                                          34        24        Median(range) 63(34-77)                     USA                                                                   RR-DTC                              Lenvatinib                   Lenvatinib 24 mg Qd, 28-day cycles
  Schlumberger M^2^   2015   III     392(lenvatinib: n=261, placebo: n=131)                                      125, 75   136, 56   Lenvatinib: median 64, placebo: median 61   USA                                                                   RR-DTC                              Lenvatinib/placebo           Lenvatinib 24 mg Qd, 28-day cycles/placebo
  Dubbelman AC        2014   I       6                                                                           3         3         Median(range) 49(34--64)                    Netherlands                                                           Advanced solid tumors; lymphomas    Lenvatinib                   Lenvatinib 24 mg Qd, 28-day cycles
  Shumaker RC         2014   I       15                                                                          11        4         Median(range) 31(20--49)                    USA                                                                   Healthy adult                       Lenvatinib plus rifampicin   Lenvatinib 24 mg/coadministrate rifampicin 600 mg
  Molina AM           2013   Ib      20                                                                          14        6         Mean(SD) 58.4(6.29)                         Finland                                                               Metastatic renal cell carcinoma     Lenvatinib plus everolimus   Lenvatinib \[12 mg (n = 7); 18 mg (n = 11); 24 mg (n = 2)\] plus everolimus 5 mg, 28-day cycles
  Boss DS             2012   I       82                                                                          43        39        Median(range) 54(25--84)                    USA                                                                   Advanced solid tumours              Lenvatinib                   Dose cohorts from 0.2 to 32 mg, 28-day cycles
  Nishio M            2013   I       28                                                                          21        7         Mean(range) 56.4(38-73)                     Japan                                                                 Non-small-cell lung cancer          Lenvatinib                   Lenvatinib 4/6 mg Bid
  Yamada K            2011   I       27                                                                          10        17        Median(range) 53(26--70)                    Japan                                                                 Advanced solid tumours              Lenvatinib                   From 0.5 to 1, 2, 4, 6, 9, 13, 16, and 20 mg Bid
  Nakamichi S         2015   I       9                                                                           2         7         Median(range) 41(30--59)                    Japan                                                                 Advanced solid tumours              Lenvatinib                   Lenvatinib \[20 mg (n = 3); 24 mg (n = 6)\], 28-day cycles
  Hong DS^2^          2015   Ib      32                                                                          20        12        Median(range) 57.5(24-81)                   USA                                                                   Advanced melanoma                   Lenvatinib plus TMZ          Dose Level (DL)1: lenvatinib 20 mg, TMZ 100 mg/m2; DL2: lenvatinib 24 mg, TMZ 100 mg/m2; DL3: lenvatinib 24 mg, TMZ 150 mg/m2, 28-day cycles
  Ikeda M             2015   I       20                                                                          17        3         Median(range) 63.5(47--74)                  Japan                                                                 Advanced hepatocellular carcinoma   Lenvatinib                   Lenvatinib 8 mg, 12 mg, 16 mg, 25 mg Qd, 4-week cycles
  Motzer RJ           2015   II      153(lenvatinib: n=52, everolimus: n=50, lenvatinib plus everolimus: n=51)   112       41        Median(range) 59(37--77)                    Czech Republic, Poland, Spain, the UK, and the USA                    Metastatic renal cell carcinoma     Lenvatinib                   Lenvatinib (24 mg/day), everolimus (10 mg/day), or lenvatinib plus everolimus (18 mg/day and 5 mg/day, respectively), 28-day cycles

MTC: medullary thyroid cancer; RR-DTC: radioiodine-refractory, differentiated thyroid cancer

Schlumberger M^1^ and ^2^: the former was a single-arm trial, while the latter was a controlled trial

Adverse drug reactions analyses {#s2_3}
-------------------------------

To evaluate the safety of lenvatinib, we calculated the rates of all-grade and grade 3 or more serious adverse events in the overall population. In single-arm trials with all-grade AEs, homogeneity existed in upper abdominal pain, arthralgia, constipation and peripheral edema etc., which were further analysed with a fixed-effects model (Figure [2a](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Others were analysed using a random-effects model (Figure [2b](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Hematuria (56.6%, 95% CI 0.193-0.877), fatigue (52.2%, 95% CI 0.384-0.657), palmar-plantar erythrodysesthesia syndrome (47.2%, 95% CI 0.201-0.761), hypertension (47.0%, 95% CI 0.354-0.589) and diarrhea (46.2%, 95% CI 0.362-0.605) were common in a random-effects model (Figure [2b](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Increased alanine aminotransferase occurred in 42% of the patients using a fixed-effects model (42.0%, 95% CI 0.294-0.556). The most frequent grade ≥ 3 treatment-related adverse events were thrombocytopenia (25.4%, 95% CI 0.055-0.665, random model), hypertension (17.7%, 95% CI 0.102-0.289, random model), peripheral edema (15.5%, 95% CI 0.020-0.622, random model) and increased aspartate aminotransferase (12.6%, 95% CI 0.061-0.242, fixed model) (Figure [2c](#F2){ref-type="fig"}, [2d](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![Forest plot of all-grade and grade ≥ 3 AEs in single-arm trials\
**a.** The all-grade adverse event rates and 95% CIs using a fixed-effects model; **b.** The all-grade adverse event rates and 95% CIs using a random-effects model; **c.** The grade ≥ 3 adverse event rates and 95% CIs using a fixed-effects model; **d.** The grade ≥ 3 adverse event rates and 95% CIs using a random-effects model.](oncotarget-07-44545-g002){#F2}

###### Summary results of the all-grade and grade ≥ 3 adverse events (AEs) with 95% confidence intervals

  All-grade adverse events                     Model          Event rate with 95% CI
  -------------------------------------------- -------------- ----------------------------
  Abdominal pain upper                         Fixed model    0.287 (0.214-0.372)
  Alanine aminotransferase increased           Fixed model    0.420 (0.294-0.556)
  Alkaline phosphatase increased               Fixed model    0.418 (0.269-0.583)
  Arthralgia                                   Fixed model    0.343 (0.264-0.431)
  Constipation                                 Fixed model    0.214 (0.161-0.278)
  Cough                                        Fixed model    0.403 (0.317-0.494)
  Dry skin                                     Fixed model    0.205 (0.139-0.292)
  Dyspnea                                      Fixed model    0.265 (0.203-0.339)
  Edema peripheral                             Fixed model    0.350 (0.250-0.466)
  Epistaxis                                    Fixed model    0.269 (0.183-0.378)
  Hypoalbuminemia                              Fixed model    0.316 (0.172-0.507)
  Hypothyroidism                               Fixed model    0.416 (0.276-0.570)
  Musculoskeletal pain                         Fixed model    0.267 (0.195-0.356)
  Pain in extremity                            Fixed model    0.292 (0.216-0.381)
  Thrombocytopenia                             Fixed model    0.263 (0.168-0.388)
  Rash                                         Fixed model    0.380 (0.224-0.566)
  Stomatitis                                   Fixed model    0.325 (0.257-0.400)
  Vomiting                                     Fixed model    0.337 (0.285-0.393)
  Abdominal pain                               Random model   0.239 (0.144-0.368)
  Anorexia                                     Random model   0.401 (0.293-0.519)
  Aspartate aminotransferase increased         Random model   0.441 (0.207-0.706)
  Blood TSH increased                          Random model   0.381 (0.203-0.597)
  Diarrhea                                     Random model   0.462 (0.326-0.605)
  Dysphonia                                    Random model   0.358 (0.266-0.463)
  Fatigue                                      Random model   0.522 (0.384-0.657)
  Headache                                     Random model   0.383 (0.228-0.565)
  Hematuria                                    Random model   0.566 (0.193-0.877)
  Hypertension                                 Random model   0.470 (0.354-0.589)
  Hypertriglyceridemia                         Random model   0.276 (0.034-0.803)
  Nausea                                       Random model   0.399 (0.324-0.478)
  Palmar-plantar erythrodysesthesia syndrome   Random model   0.472 (0.201-0.761)
  Proteinuria                                  Random model   0.430 (0.309-0.560)
  Weight loss                                  Random model   0.378 (0.224-0.562)
  **Grade ≥ 3 adverse events**                 **Model**      **Event rate with 95% CI**
  Abdominal pain                               Fixed model    0.024 (0.008-0.073)
  Abdominal pain upper                         Fixed model    0.017 (0.004-0.066)
  Alkaline phosphatase increased               Fixed model    0.074 (0.028-0.182)
  Anemia                                       Fixed model    0.083 (0.038-0.173)
  Anorexia                                     Fixed model    0.049 (0.026-0.090)
  Arthralgia                                   Fixed model    0.039 (0.015-0.100)
  Aspartate aminotransferase increased         Fixed model    0.126 (0.061-0.242)
  diarrhea                                     Fixed model    0.094 (0.065-0.134)
  Dyspnea                                      Fixed model    0.045 (0.014-0.131)
  Fatigue                                      Fixed model    0.067 (0.043-0.103)
  Headache                                     Fixed model    0.031 (0.010-0.093)
  Hyponatremia                                 Fixed model    0.052 (0.017-0.149)
  Nausea                                       Fixed model    0.047 (0.024-0.093)
  Proteinuria                                  Fixed model    0.077 (0.053-0.109)
  Vomiting                                     Fixed model    0.040 (0.013-0.118)
  Weight loss                                  Fixed model    0.080 (0.050-0.127)
  Edema peripheral                             Random model   0.155 (0.020-0.622)
  Hypertension                                 Random model   0.177 (0.102-0.289)
  Palmar-plantar erythrodysesthesia syndrome   Random model   0.076 (0.017-0.284)
  Thrombocytopenia                             Random model   0.254 (0.055-0.665)

Survival outcomes and subgroup analysis {#s2_4}
---------------------------------------

The efficacy analysis of lenvatinib was mainly based on the controlled trial of lenvatinib in patients with thyroid cancer \[[@R22]\]. The median progression-free survival was 18.3 months in the lenvatinib group and 3.6 months in the placebo group (hazard ratio for progression or death 0.21, 99% CI 0.14-0.31, P \< 0.001). In addition, Motzer RJ \[[@R19]\] reported that median PFS was 7.4 months (95% CI 5.6-10.2) for single-agent lenvatinib in patients with metastatic renal cell carcinoma and 5.5 months (95% CI 3.5-7.1) for single-agent everolimus, representing the significantly prolonged PFS of lenvatinib compared with everolimus alone (HR 0.61, 95% CI 0.38-0.98, p = 0.048). Seven trials \[[@R13], [@R15], [@R16], [@R19], [@R22], [@R25], [@R26]\] reported encouraging response rates, median time to response, or PFS observed in patients with different types of tumors, demonstrating the anti-tumour efficacy of lenvatinib (Table [3](#T3){ref-type="table"}). We further carried out subgroup analyses according to tumor types. Mean PFS for renal cell carcinoma was 10.933 ± 1.828 months (95% CI 7.350-14.515, p \< 0.001), and that for thyroid cancer was 18.344±0.083 months (95% CI 18.181-18.506, p \< 0.001) (Table [4](#T4){ref-type="table"}). Further large-scale studies are still needed to assess the PFS of patients with melanoma and non-small-cell lung cancer.

###### The median PFS of the included trials

  -------------------------------------------------------------------------------------------------------------------------
  Study                    Sample\   Tumor types                  Median PFS (95%CI)\   Mean     SD     Overall median OS
                           size                                   (Months)                              
  ------------------------ --------- ---------------------------- --------------------- -------- ------ -------------------
  Boss DS 2012             9         renal cell carcinoma         15.9 (9.3-18.63)      14.93    2.75   

                           14        melanoma                     7.23 (3.63-12.63)     7.68     2.61   

  Schlumberger M^1^ 2015   59        MTC                          9.0 (7-16.6)          6.25     2.4    16.6 (16.4-NE)

  Cabanillas ME 2015       58        RR-DTC                       12.6 (9.9-16.1)       12.8     1.55   

  Molina AM 2014           20        renal cell carcinoma         11 (5.23-14.87)       10.525   2.41   

  Nishio M 2013            28        non-small-cell lung cancer   9.0 (6.5-9.5)         8.5      0.75   

  Schlumberger M^2^ 2015   392       RR-DTC                       18.3 (15.2-26)        19.45    1.8    

  Motzer RJ 2015           153       renal cell carcinoma         7.4 (5.6-10.2)        7.65     0.77   
  -------------------------------------------------------------------------------------------------------------------------

SD: Standard deviation estimation

MTC: medullary thyroid cancer

RR-DTC: radioiodine-refractory, differentiated thyroid cancer

Martin schlumberger ^1^ and ^2^: the former was a single-arm trial, while the latter was a controlled trial

###### Subgroup analysis for survival outcomes

  First author             Model    Mean     Standard error   Variance   95% CI   Z-Value   P-Value   Histology   
  ------------------------ -------- -------- ---------------- ---------- -------- --------- --------- ----------- --------
  Cabanillas ME 2015                12.800   0.204            0.041      12.401   13.199    62.892                RR-DTC
  Schlumberger M^2^ 2015            19.450   0.091            0.008      19.272   19.628    213.933               RR-DTC
  Overall                  Random   18.344   0.083            0.007      18.181   18.506    220.987   \< 0.001    
  Molina AM 2014                    10.525   0.539            0.290      9.469    11.581    19.531                RCC
  Boss DS 2012                      14.930   0.917            0.840      13.133   16.727    16.287                RCC
  Motzer RJ 2015                    7.650    0.062            0.004      7.528    7.772     122.890               RCC
  Overall                  Random   10.933   1.828            3.341      7.350    14.515    5.981     \< 0.001    

MTC: medullary thyroid cancer

RR-DTC: radioiodine-refractory, differentiated thyroid cancer

RCC: Renal cell carcinoma

Schlumberger M^1^ and ^2^: the former was a single-arm trial, while the latter was a controlled trial

Risk of bias and quality assessment {#s2_5}
-----------------------------------

The risk of bias and quality assessments of the included studies are outlined in Figure [3a](#F3){ref-type="fig"}, [3b](#F3){ref-type="fig"}. Overall, the quality of the studies was satisfactory.

![Risk of bias and quality assessment\
**a.** Risk of bias graph: review authors\' judgments about each risk of bias item presented as percentages across all included studies; **b.** Risk of bias summary: review authors\' judgments about each risk of bias item for each included study.](oncotarget-07-44545-g003){#F3}

DISCUSSION {#s3}
==========

To the best of our knowledge, this is the first study to evaluate both the safety and efficacy of the novel antitumor agent lenvantinib in different types of tumors systematically. The adverse events of lenvatinib were tyrosine kinase inhibitor-related and were also seen in other TKIs. In one meta-analysis \[[@R27]\], the VEGFR-TKIs group (cediranib and axitinib) was associated with higher rates of diarrhea, fatigue, hypertension and thrombocytopenia compared with bevacizumab. Vandetanib \[[@R28]\], a dual VEGFR and EGFR inhibitor, yielded an improvement in PFS but more frequent grade 3 or greater hypertension. Although the incidence of hematuria was high, most people experienced low grade (grade 0) hematuria.

It should be noted that lenvatinib was associated with a significantly increased risk in all-grade (47.0%) and high-grade (17.7%) hypertension. The mechanism of lenvatinib-associated hypertension has not been clarified, and may be due to a possible perturbation of endothelial cell function in patients treated with VEGF-targeting agents \[[@R29]\]. It has been documented upon administration of bevacuzimab and cediranib, and several other inhibitors of the VEGF signalling pathway \[[@R30]--[@R32]\]. All of these suggest that patients who were administered lenvatinib should be monitored for high blood pressure, and managed with antihypertensive drugs or dose reductions when necessary.

Grade ≥ 3 thrombocytopenia was experienced in about a quarter of patients. Through binding to PDGFR, PDGF promotes the recovery of platelets and the formation of bone marrow colony-forming unit-megakaryocyte \[[@R33], [@R34]\], thus the inhibition of PDGFR by lenvatinib might cause thrombocytopenia. Hematopoietic growth factors and transfusions \[[@R35]\] could be used to deal with persistent toxicities on platelets, but the effects of them on tumor cells remain to be explored.

In February 2015, US FDA has approved lenvatinib for the treatment of radioiodine-refractory thyroid cancer \[[@R9]\] based on the randomized controlled trial \[[@R22]\] included in our analysis. We find a similar mean PFS (18.344±0.083 months, 95% CI 18.181-18.506, p \< 0.001) for thyroid cancer in our pooled analysis. However, our results of adverse events (Figure [4a](#F4){ref-type="fig"}, [4b](#F4){ref-type="fig"}) are different, since the relatively larger sample size may allow us to better determine the AE values. Survival outcomes of other tumors are mainly based on phase I and phase II trials, and more subsequent randomized, controlled phase III trials are needed.

![The odds ratios (ORs) of adverse events (AEs) in a controlled trial comparing lenvatinib and placebo\
**a.** OR and 95% CIs of all-grade AEs using a random-effects model; **b.** OR and 95% CIs of grade ≥ 3 AEs using a fixed-effects model.](oncotarget-07-44545-g004){#F4}

The dose of lenvatinib administered in patients with solid tumors varied in different situations, but in 8 \[[@R15], [@R16], [@R18]--[@R20], [@R22], [@R23], [@R26]\] of the 14 included studies, patients received lenvatinib at a daily dose of 24 mg per day in 28-day cycles, and two studies \[[@R18], [@R20]\] demonstrated that the 24-mg QD dose of lenvatinib was determined to be tolerable with encouraging anti-tumor activity in patients with solid tumors.

The heterogeneity in our analysis could arise from different tumor types, the very heterogeneous study population with pre-treated disease and the ethnicity difference. In addition, there are several limitations of our study. Firstly, because lenvatinib is a relatively new drug, reports about it are few and are mostly phase I and II studies. Secondly, only one study provided the overall survival data, so prolonged follow-ups are needed. Thirdly, we did not perform subgroup analysis of melanoma and non-small-cell lung cancer because of lack of enough information.

In conclusion, lenvatinib has clinically meaningful benefits in survival outcomes of patients with thyroid cancer. The pooled analyses suggest that patients should be monitored for potential thrombocytopenia and increases in blood pressure, and dose reductions or delays or antihypertensive drugs are needed accordingly. Correct estimates of treatment-related toxicities and the efficacy of lenvatinib are fundamental to provide appropriate guidance and to conduct ongoing trials.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We performed a literature search of PubMed, Medline, Embase, Web of Science and The Cochrane Library for all the relevant clinical trials on the safety and efficacy of lenvatinib (until April 26, 2016, 201). In order to ensure the completeness of the results, we expanded the search scope by using the search terms "lenvatinib" or "E7080" or "lenvima". We also carried out further searches for relevant unpublished trials in the clinical trial registry ([http://www.clinicaltrials.gov](http://www.clinicaltrials.gov/)). Papers in all languages were sought and translated where appropriate to reduce the chances of bias.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

To be included in the analysis, patients must be diagnosed with histologically confirmed tumors, survival outcomes and toxicities were mandatory to be reported. All phase clinical trials were eligible for inclusion if they evaluated the side effects and efficacy of lenvatinib. Studies were excluded if they did not provide enough data for toxicities and survival outcomes. They were also excluded for which full-text reports were not available.

Selection process and data extraction {#s4_3}
-------------------------------------

Two reviewers selected studies independently. Any disagreements were resolved through discussion with another author. We excluded those studies that clearly did not meet the inclusion criteria, and made efforts to rule out duplicated studies by comparing author lists, publication year, and the main contents if necessary. Articles with the same author(s) or medical center(s) were carefully reviewed and discussed for eligibility.

Data extracted from all eligible articles included the first author, year of publication, sample size, study phase, tumor type, treatment regime, progression-free survival (PFS), hazard ratio (HR) and adverse events. ADRs were graded using the National Cancer Institute (Washington, DC, USA) Common Toxicity Criteria, version 3.0.

Data analysis {#s4_4}
-------------

We used patients\' all-grade and grade ≥ 3 Common Toxicity Criteria Adverse Events (CTCAE) counts to calculate the incidence rates of AEs and the corresponding 95% confidence intervals (CIs). I-squared was calculated to test heterogeneity of the studies, and I^2^ \> 50% and P ≤ 0.1 indicated strong heterogeneity between the studies. All the analysis was carried out using the software Comprehensive Meta-Analysis (CMA) program 2 (Biostat, Englewood, NJ) and Review manager 5.3 (Copenhagen, Sweden).

Risk of bias and quality assessment {#s4_5}
-----------------------------------

To evaluate the risk of bias and quality of the studies, QUADAS-2 was used as a systematic review assessment method, which consisted of four key domains: patient selection, index test, reference standard and flow and timing \[[@R36]\]. Risk of bias was rated as high/low/unclear. The assessment was measured using Review Manager 5.3 (Copenhagen, Sweden).
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